We are very pleased to welcome Gradient Denervation Technologies (“Gradient”) to the Thuja family. Gradient, the seventh investment from our third fund, is the latest addition to the Thuja portfolio of companies. Gradient is a clinical-stage company developing an innovative, minimally invasive ultrasound-based catheter device for the treatment of pulmonary hypertension.
Gradient will initially focus on patients with pulmonary hypertension due to left-sided heart disease, which affects several million individuals across the US and Europe. There are currently no targeted treatments available for this disease, which has significant negative impacts on quality and length of life.
Evan Castiglia, Partner at Thuja says,: “Gradient has significant potential to improve the care of patients with pulmonary hypertension due to left heart disease, a patient group with a substantial need for better treatment solutions. We are excited to support the Gradient team as they pursue this mission.”
We congratulate CEO Martin Grasse and his team with the €14M Series A funding round and look forward to working with co-investors Asabys Partners and Sofinnova Partners.
Read full press-release here.